Vera Therapeutics, Inc.

BRISBANE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on November 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 14,900 shares of Class A common stock and restricted stock units (RSUs) underlying 7,450 shares of Class A common stock to three (3) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).

Vera Therapeutics NASDAQ: VERA reported $10.3 million in third-quarter TRUTAKNA sales, its first partial quarter of commercial revenue, as the company pursues full U.S. approval for the kidney disease treatment.

Vera Therapeutics, Inc. (VERA) Q3 2026 Earnings Call Transcript

Vera Therapeutics, Inc. (VERA) came out with a quarterly loss of $1.3 per share versus the Zacks Consensus Estimate of a loss of $1.72. This compares to a loss of $1.26 per share a year ago.